Skip to main content

Advertisement

Log in

Alzheimer's disease market: hope deferred

  • From the Analyst's Couch
  • Published:

From Nature Reviews Drug Discovery

View current issue Sign up to alerts

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Figure 1: The mode of action categories of developmental drugs across clinical Phase I, II and III trials.
Figure 2: Aggregate sales forecast by active pharmaceutical ingredient in the top seven developed markets.

References

  1. Wischik, C. M. et al. O3-04-07: Tau aggregation inhibitor (TAI) therapy with Rember arrests disease progression in mild and moderate Alzheimer's disease over 50 weeks. Alzheimers Dement. 4, T167 (2008).

    Article  Google Scholar 

  2. Mullard,A. Sting of Alzheimer's failures offset by upcoming prevention trials. Nature Rev. Drug Discov. 11, 657–660 (2012).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Waldemar Ockert.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Related links

Related links

FURTHER INFORMATION

Author's homepage

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gerald, Z., Ockert, W. Alzheimer's disease market: hope deferred. Nat Rev Drug Discov 12, 19–20 (2013). https://doi.org/10.1038/nrd3922

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd3922

  • Springer Nature Limited

This article is cited by

Navigation